Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Shoji, Emi ^a,b   Sakurai, Hidetoshi ^a   Nishino, Tokiko ^a   Nakahata, Tatsutoshi ^a   Heike, Toshio ^c   Awaya, Tomonari ^c   Fujii, Nobuharu ^e   Manabe, Yasuko ^e   Matsuo, Masafumi ^d   Sehara Fujisawa, Atsuko ^b  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d KOBE GAKUIN UNIVERSITY   (Japan)

^e TOKYO METROPOLITAN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CALCIUM; DYSTROPHIN; MYOD PROTEIN; TETRACYCLINE;

ADULT; BIOLOGICAL MODEL; CELL DIFFERENTIATION; DRUG EFFECTS; ELECTROSTIMULATION; EXON; GENETIC TRANSFECTION; GENETICS; HUMAN; INDUCED PLURIPOTENT STEM CELL; INFANT; MALE; METABOLISM; MUSCULAR DYSTROPHY, DUCHENNE; PATHOLOGY; SKELETAL MUSCLE CELL;

ADULT; CALCIUM; CELL DIFFERENTIATION; DYSTROPHIN; ELECTRIC STIMULATION; EXONS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; INFANT; MALE; MODELS, BIOLOGICAL; MUSCLE FIBERS, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; MYOD PROTEIN; OLIGONUCLEOTIDES, ANTISENSE; TETRACYCLINE; TRANSFECTION;

EID: 84939638032     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12831     Document Type: Article

References (43)

1. Fairclough, R. J., Wood, M. J., Davies, K. E. Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat Rev Genet 14, 373-378, doi: 10.1038/nrg3460 (2013).
2. Nowak, K. J., Davies, K. E. Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep 5, 872-876, doi: 10.1038/sj.embor.7400221 (2004).
3. Hoffman, E. P., Knudson, C. M., Campbell, K. P., Kunkel, L. M. Subcellular fractionation of dystrophin to the triads of skeletal muscle. Nature 330, 754-758, doi: 10.1038/330754a0 (1987).
4. White, S. et al. Comprehensive detection of genomic duplications and deletions in the DMD gene, by use of multiplex amplifiable probe hybridization. Am J Hum Genet 71, 365-374, doi: 10.1086/341942 (2002).
5. Kinali, M. et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8, 918-928, doi: 10.1016/S1474-4422(09)70211-X (2009).
6. Muntoni, F., Wood, M. J. A. Targeting RNA to treat neuromuscular disease. Nature Reviews Drug Discovery 10, 621-637, doi: 10.1038/Nrd3459 (2011).
7. Tremblay, J. P. CSCI/RCPSC Henry Friesen Lecture: Cell therapy for Duchenne muscular dystrophy. Clinical and investigative medicine. Medecine clinique et experimentale 29, 378-382 (2006).
8. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872, doi: 10.1016/j.cell.2007.11.019 (2007).
9. Hirata, S. et al. Congenital amegakaryocytic thrombocytopenia iPS cells exhibit defective MPL-mediated signaling. J Clin Invest 123, 3802-3814, doi: 10.1172/JCI64721 (2013).
10. Kondo, T. et al. Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. Cell stem cell 12, 487-496, doi: 10.1016/j.stem.2013.01.009 (2013).
11. Blau, H. M., Webster, C., Pavlath, G. K. Defective myoblasts identified in Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences of the United States of America 80, 4856-4860 (1983).
12. Delaporte, C., Dautreaux, B., Rouche, A., Fardeau, M. Changes in surface morphology and basal lamina of cultured muscle cells from Duchenne muscular dystrophy patients. Journal of the neurological sciences 95, 77-88 (1990).
13. Webster, C., Blau, H. M. Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: implications for cell and gene therapy. Somatic cell and molecular genetics 16, 557-565 (1990).
14. Decary, S. et al. Shorter telomeres in dystrophic muscle consistent with extensive regeneration in young children. Neuromuscular disorders: NMD 10, 113-120 (2000).
15. Ebashi, S., Toyokura, Y., Momoi, H., Sugita, H. High Creatine Phosphokinase Activity of Sera of Progressive Muscular Dystrophy. Journal of Biochemistry 46, 103-104 (1959).
16. Menazza, S. et al. Oxidative stress by monoamine oxidases is causally involved in myofiber damage in muscular dystrophy. Human molecular genetics 19, 4207-4215, doi: 10.1093/hmg/ddq339 (2010).
17. Evans, N. P., Misyak, S. A., Robertson, J. L., Bassaganya-Riera, J., Grange, R. W. Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention. PM & R: the journal of injury, function, and rehabilitation 1, 755-768, doi: 10.1016/j.pmrj.2009.04.010 (2009).
18. Badalamente, M. A., Stracher, A. Delay of muscle degeneration and necrosis in mdx mice by calpain inhibition. Muscle & nerve 23, 106-111 (2000).
19. Iwata, Y., Katanosaka, Y., Arai, Y., Shigekawa, M., Wakabayashi, S. Dominant-negative inhibition of Ca2+ influx via TRPV2 ameliorates muscular dystrophy in animal models. Human molecular genetics 18, 824-834, doi: 10.1093/hmg/ddn408 (2009).
20. Millay, D. P. et al. Calcium influx is sufficient to induce muscular dystrophy through a TRPC-dependent mechanism. Proceedings of the National Academy of Sciences of the United States of America 106, 19023-19028, doi: 10.1073/Pnas.0906591106 (2009).
21. Vandebrouck, C., Martin, D., Schoor, M. C. V., Debaix, H., Gailly, P. Involvement of TRPC in the abnormal calcium influx observed in dystrophic (mdx) mouse skeletal muscle fibers. J Cell Biol 158, 1089-1096, doi: 10.1083/Jcb.200203091 (2002).
22. Constantin, B., Sebille, S., Cognard, C. New insights in the regulation of calcium transfers by muscle dystrophin-based cytoskeleton: implications in DMD. J Muscle Res Cell Motil 27, 375-386, doi: 10.1007/s10974-006-9085-2 (2006).
23. Harisseh, R., Chatelier, A., Magaud, C., Deliot, N., Constantin, B. Involvement of TRPV2 and SOCE in calcium influx disorder in DMD primary human myotubes with a specific contribution of alpha1-syntrophin and PLC/PKC in SOCE regulation. Am J Physiol Cell Physiol 304, C881-894, doi: 10.1152/ajpcell.00182.2012 (2013).
24. Allen, D. G., Whitehead, N. P. Duchenne muscular dystrophy-what causes the increased membrane permeability in skeletal muscle? Int J Biochem Cell Biol 43, 290-294, doi: 10.1016/j.biocel.2010.11.005 (2011).
25. Nakagawa, M., Takizawa, N., Narita, M., Ichisaka, T., Yamanaka, S. Promotion of direct reprogramming by transformationdeficient Myc. Proceedings of the National Academy of Sciences of the United States of America 107, 14152-14157, doi: 10.1073/pnas.1009374107 (2010).
26. Tanaka, A. et al. Efficient and reproducible myogenic differentiation from human iPS cells: prospects for modeling Miyoshi Myopathy in vitro. PLoS One 8, e61540, doi: 10.1371/journal.pone.0061540 (2013).
27. Tapscott, S. J. et al. MyoD1: a nuclear phosphoprotein requiring a Myc homology region to convert fibroblasts to myoblasts. Science 242, 405-411 (1988).
28. Hashimoto, N. et al. Immortalization of human myogenic progenitor cell clone retaining multipotentiality. Biochemical and biophysical research communications 348, 1383-1388, doi: 10.1016/j.bbrc.2006.08.006 (2006).
29. Tiso, N. et al. Fine mapping of five human skeletal muscle genes: alpha-tropomyosin, beta-tropomyosin, troponin-I slow-twitch, troponin-I fast-twitch, and troponin-C fast. Biochemical and biophysical research communications 230, 347-350, doi: 10.1006/bbrc.1996.5958 (1997).
30. Manabe, Y. et al. Characterization of an acute muscle contraction model using cultured C2C12 myotubes. PLoS One 7, e52592, doi: 10.1371/journal.pone.0052592 (2012).
31. Aartsma-Rus, A., Van Ommen, G. J. B. Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications. Rna 13, 1609-1624, doi: 10.1261/Rna.653607 (2007).
32. Malueka, R. G. et al. Antisense oligonucleotide induced dystrophin exon 45 skipping at a low half-maximal effective concentration in a cell-free splicing system. Nucleic acid therapeutics 21, 347-353, doi: 10.1089/nat.2011.0310 (2011).
33. Iwata, Y. et al. A novel mechanism of myocyte degeneration involving the Ca2+ ?permeable growth factor-regulated channel. J Cell Biol 161, 957-967, doi: 10.1083/jcb.200301101 (2003).
34. Liu, C., Hermann, T. E. Characterization of ionomycin as a calcium ionophore. J Biol Chem 253, 5892-5894 (1978).
35. Vriens, J., Appendino, G., Nilius, B. Pharmacology of Vanilloid Transient Receptor Potential Cation Channels. Molecular Pharmacology 75, 1262-1279, doi: 10.1124/Mol.109.055624 (2009).
36. Delaporte, C., Dehaupas, M., Fardeau, M. Comparison between the growth pattern of cell cultures from normal and Duchenne dystrophy muscle. Journal of the neurological sciences 64, 149-160 (1984).
37. Cazzella, V. et al. Exon 45 skipping through U1-snRNA antisense molecules recovers the Dys-nNOS pathway and muscle differentiation in human DMD myoblasts. Mol Ther 20, 2134-2142, doi: 10.1038/mt.2012.178 (2012).
38. Yokota, T., Duddy, W., Partridge, T. Optimizing exon skipping therapies for DMD. Acta myologica: myopathies and cardiomyopathies: official journal of the Mediterranean Society of Myology/edited by the Gaetano Conte Academy for the study of striated muscle diseases 26, 179-184 (2007).
39. Blake, D. J., Weir, A., Newey, S. E., Davies, K. E. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiological reviews 82, 291-329, doi: 10.1152/physrev.00028.2001 (2002).
40. Christensen, A. P., Corey, D. P. TRP channels in mechanosensation: direct or indirect activation? Nat Rev Neurosci 8, 510-521, doi: 10.1038/nrn2149 (2007).
41. Brinkmeier, H. TRP channels in skeletal muscle: gene expression, function and implications for disease. Advances in experimental medicine and biology 704, 749-758, doi: 10.1007/978-94-007-0265-3-39 (2011).
42. Grskovic, M., Javaherian, A., Strulovici, B., Daley, G. Q. Induced pluripotent stem cells-opportunities for disease modelling and drug discovery. Nature reviews. Drug discovery 10, 915-929, doi: 10.1038/nrd3577 (2011).
43. Takagi, M. et al. Design of 2?-O-Me RNA/ENA chimera oligonucleotides to induce exon skipping in dystrophin pre-mRNA. Nucleic acids symposium series, 297-298, doi: 10.1093/nass/48.1.297 (2004).